ChemoMetec Acquires Ovizio Imaging Systems SA
ChemoMetec has taken an important step by submitting a binding tender offer for the complete acquisition of Belgian company Ovizio Imaging Systems SA. This decision comes after careful consideration and a thorough due diligence process.
Details of the Acquisition
The acquisition is set at a price of EUR 2,830,000. Exciting news: the tender offer has captured the acceptance of shareholders owning over two-thirds of Ovizio. ChemoMetec is now focused on securing consent from the remaining shareholders, who have the legal obligation to contribute.
Expectedly, the closing of this deal is projected to happen within a week, marking the official start of ChemoMetec's integration and development of Ovizio’s operations.
Future Developments and Impacts
Once the acquisition is finalized, ChemoMetec plans to roll out developmental measures aimed at enhancing Ovizio's offerings. Importantly, ChemoMetec assures that acquiring Ovizio will not alter its latest guidance and forecasts.
About Ovizio Imaging Systems
Ovizio Imaging Systems is recognized for its innovative cell counter developed with holographic microscopy technology. This device is extensively used in bioprocessing as well as in the realms of cellular and gene therapy. A standout feature of Ovizio’s product is its direct integration with customers' bioreactors via a high-cleanliness, disposable item that ensures sterilization.
The cell counter allows for the continuous extraction of cells from bioreactors for analysis, with the provision to return them afterward. Ovizio's clientele includes esteemed names in the pharmaceutical and biotech industries. They reported revenues of EUR 1.4 million in 2023, with a sizable portion coming from the sales of consumables and service contracts.
About ChemoMetec A/S
ChemoMetec A/S specializes in the development, manufacturing, and marketing of cutting-edge instruments for cell counting and various other measurements. Their instruments cater primarily to the pharmaceutical, biotech, and agricultural sectors globally.
Since its establishment in 1997, ChemoMetec has formed partnerships with some of the world's leading pharmaceutical companies, establishing a strong reputation in the market. The company is listed on Nasdaq OMX Copenhagen.
Contact Information
If you need additional details or have inquiries regarding the acquisition, please reach out to:
Martin Helbo Behrens, CEO
Phone: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Phone: (+45) 48 13 10 20
Frequently Asked Questions
1. What is the acquisition price for Ovizio Imaging Systems?
The acquisition price is set at EUR 2,830,000.
2. How much of Ovizio's shares have already been accepted?
Shareholders owning more than two-thirds of Ovizio have accepted the tender offer.
3. Will the acquisition affect ChemoMetec’s guidance?
ChemoMetec confirms that the acquisition will not impact its most recent guidance.
4. What technology does Ovizio specialize in?
Ovizio specializes in holographic microscopy for cell counting, particularly in bioprocessing and gene therapy.
5. When is the closing of the acquisition expected?
The closing is expected to take place within the coming week.
